| Q40641201 | 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts |
| Q44291815 | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases |
| Q34159735 | A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation |
| Q34283353 | A role for parathyroid hormone-related protein in the pathogenesis of inflammatory/autoimmune diseases |
| Q74055954 | Activation of osteoclasts by interleukin-1: divergent responsiveness in osteoclasts formed in vivo and in vitro |
| Q48025236 | Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse |
| Q44216694 | An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6. |
| Q35145622 | Biology of the TRANCE axis |
| Q24805142 | Bone loss. Factors that regulate osteoclast differentiation: an update |
| Q35597152 | CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin |
| Q24646547 | Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice |
| Q46585287 | Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms |
| Q40710871 | Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells |
| Q37396070 | Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease |
| Q97423931 | Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice |
| Q53643332 | Effects of anti-parathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice. |
| Q31120838 | Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases |
| Q64380111 | Establishment of a new murine model of hypercalcemia with anorexia by overexpression of soluble receptor activator of NF-κB ligand using an adenovirus vector |
| Q33585182 | Excessive dietary intake of vitamin A reduces skull bone thickness in mice |
| Q35213959 | Exploring the mechanisms regulating regeneration of deer antlers |
| Q90442956 | Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond |
| Q43825443 | Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression |
| Q44245391 | Increased levels of osteoprotegerin in hemodialysis patients |
| Q36417317 | Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies |
| Q40038407 | Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis |
| Q36610803 | Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. |
| Q35553437 | Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha |
| Q88220668 | Interleukin-1-induced acute bone resorption facilitates the secretion of fibroblast growth factor 23 into the circulation |
| Q40551497 | Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis |
| Q53955124 | LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. |
| Q36968961 | Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement |
| Q38425187 | Local delivery of recombinant osteoprotegerin enhances postorthodontic tooth stability |
| Q37207329 | Marker of Bone Resorption in Acute Response to Exogenous or Endogenous Parathyroid Hormone |
| Q34106530 | Molecular control of bone remodeling and osteoporosis |
| Q36943671 | Multifunctional coatings to simultaneously promote osseointegration and prevent infection of orthopaedic implants |
| Q33944735 | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression |
| Q84448617 | Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats |
| Q29547556 | Osteoclast differentiation and activation |
| Q34560598 | Osteoprotegerin |
| Q74414282 | Osteoprotegerin ameliorates sciatic nerve crush induced bone loss |
| Q34079327 | Osteoprotegerin ligand: a regulator of immune responses and bone physiology. |
| Q47776871 | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice |
| Q35789185 | Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis |
| Q36368706 | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis |
| Q34008809 | P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption |
| Q34437610 | PTH and PTHrP effects on the skeleton |
| Q35122555 | Perspectives on osteoporosis in pediatric inflammatory bowel disease |
| Q51652972 | Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats. |
| Q37307876 | Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy. |
| Q37108966 | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism |
| Q28570898 | RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies |
| Q37532561 | RANKL inhibition for the management of patients with benign metabolic bone disorders. |
| Q36860987 | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. |
| Q34086847 | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases |
| Q35083436 | Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis |
| Q35652505 | Role for osteoprotegerin in rheumatoid inflammation |
| Q34963016 | Role of RANKL and RANK in bone loss and arthritis. |
| Q38215027 | Role of periodontal ligament fibroblasts in osteoclastogenesis: a review |
| Q50673485 | Sortase A-aided Escherichia coli expression system for functional osteoprotegerin cysteine-rich domain. |
| Q34147627 | The 18 kDa translocator protein (peripheral benzodiazepine receptor) expression in the bone of normal, osteoprotegerin or low calcium diet treated mice |
| Q35598495 | The development of supportive-care agents for patients with cancer |
| Q42200484 | The effects of dried root aqueous extract of Salvia miltiorrhiza and its major ingredient in acceleration of orthodontic tooth movement in rat |
| Q80528277 | The effects of osteoprotegerin on the mechanical properties of rat bone |
| Q36491430 | The role of the bone microenvironment in skeletal metastasis. |
| Q36246863 | Therapeutic Effects of Cortex acanthopanacis Aqueous Extract on Bone Metabolism of Ovariectomized Rats |
| Q38904914 | Transmembrane protein 173 inhibits RANKL-induced osteoclast differentiation |
| Q33886695 | Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction |
| Q43937881 | Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin |